CMS Open Payments · Program Year 2024
Delcath Systems
Delcath Systems reported $329,615.99 across General Payments, Research, and Ownership to 397 physicians and teaching hospitals across 397 transactions.
- $329.6K
- All-tracks total
- 397
- Transactions
- 397
- Recipients
- #871
- of 1,925 companies
Delcath Systems reported $329,615.99 across all CMS Open Payments tracks (General + Research + Ownership) to 397 physicians and teaching hospitals in Program Year 2024 - ranking #871 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $329,615.99, averaging $830.27 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer delcath-systems Delcath Systems
$329.6K · #871/1,925 · 0.0% industry · PY2024
- TOT $329.6K
- RANK #871
- SHARE 0.0%
- TXN 397
- RCP 397
- CAT 3
- GEN $329.6K
- TOP1 18.6%
- PY 2024
Volume peers
Nearest volume peer: Mindera Corp ($329.6K)
Delcath Systems sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Delcath Systems
Rank #871 of 1,925 companies in CMS Open Payments for 2024 belongs to Delcath Systems, which reported $329,615.99 across 397 transactions to 397 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $830.27 per transaction and $830.27 per recipient.
48 transactions worth $198.6K make "Consulting Fee" the top general-payment category in the 3-category breakdown below, 60.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 3 types of general payments, Delcath Systems's largest category was "Consulting Fee" at $198.6K - 60.2% of General Payments.
How Delcath Systems divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $198.6K | 48 | 60.2% |
| Travel and Lodging | $107.5K | 111 | 32.6% |
| Food and Beverage | $23.5K | 238 | 7.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $186,783.21 (56.7%) of $329,615.99 in this company's General Payments records across 136 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Delcath Systems
The five named recipients with the highest reported General Payments from this company
- 1
Siddharth Padia
$61,273.61 across 24 reported transactions
- 2
Chang Hwa Mary Chen
$52,209.74 across 35 reported transactions
- 3
Venkatesh Krishnasamy
$32,791.10 across 24 reported transactions
- 4
Dane Saksa
$25,848.53 across 16 reported transactions
- 5
Ryan Dalton
$14,660.23 across 9 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Delcath Systems's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Delcath Systems.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Delcath Systems.
Showing 6 of 1,924 companies with CMS-reported payment data.
Azurity Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc.
Life Spine, Inc.
Brainsway USA INC
BioCryst Pharmaceuticals, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.